Incidence and Predictors of Urotoxic Adverse Events in Cyclophosphamide-Treated Patients With Systemic Necrotizing Vasculitides

被引:60
作者
Le Guenno, Guillaume [1 ,2 ]
Mahr, Alfred [1 ,2 ]
Pagnoux, Christian [1 ,2 ]
Dhote, Robin [3 ,4 ]
Guillevin, Loic [1 ,2 ]
机构
[1] Hop Cochin, AP HP, F-75674 Paris, France
[2] Univ Paris 05, Paris, France
[3] Hop Avicenne, AP HP, F-93009 Bobigny, France
[4] Univ Paris 13, Bobigny, France
来源
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 05期
关键词
CHURG-STRAUSS-SYNDROME; POOR-PROGNOSIS FACTORS; TRIAL COMPARING GLUCOCORTICOIDS; INDUCED HEMORRHAGIC CYSTITIS; ANCA-ASSOCIATED VASCULITIS; NON-HODGKINS-LYMPHOMA; HEPATITIS-B-VIRUS; WEGENERS-GRANULOMATOSIS; POLYARTERITIS-NODOSA; PULSE CYCLOPHOSPHAMIDE;
D O I
10.1002/art.30296
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess hemorrhagic cystitis and urinary tract cancer incidence and predictors in cyclophosphamide (CYC)-treated patients with systemic necrotizing vasculitis (SNV). Methods. The French Vasculitis Study Group database, which contains longitudinal data on SNV patients, was searched for urinary tract cancer and/or hemorrhagic cystitis occurrences in patients diagnosed as having Wegener's granulomatosis (WG), microscopic polyangiitis, Churg-Strauss syndrome, or polyarteritis nodosa. The observed incidence of urinary tract cancer was compared to the expected incidence in the general population by calculating standardized incidence ratios (SIRs). Relationships between urinary tract cancer and/or hemorrhagic cystitis and 10 variables, including CYC dosage and administration route, were investigated by survival analyses for a nested subgroup of patients for whom detailed information on CYC exposure was available. Results. Among the 805 patients observed over 4,230 patient-years (mean followup 5.3 years), 22 cases of hemorrhagic cystitis and 7 of urinary tract cancer were identified in 27 patients. The SIRs for urinary tract cancer were 5.00 for all patients with SNV (P = 0.001) and 5.96 for patients with WG (P = 0.03). Based on 467 patients with detailed CYC information, cumulative CYC dose (hazard ratio [HR] for 10-gm increments 1.09; P = 0.03), ever-oral CYC administration (HR 5.50; P = 0.001), and WG (HR 2.96; P = 0.01) independently predicted urinary tract cancer and/or hemorrhagic cystitis. According to univariate analyses, smoking (ever) (HR 8.20; P = 0.02) and a prior hemorrhagic cystitis episode (HR 5.20; P = 0.046) significantly predicted urinary tract cancer. Conclusion. Our findings indicate that CYC treatment of SNV is associated with a 5-fold higher risk of developing urinary tract cancer. Urotoxicity risk in SNV is associated with the cumulative CYC dose and its oral administration, and might be higher in WG.
引用
收藏
页码:1435 / 1445
页数:11
相关论文
共 56 条
  • [1] [Anonymous], 2002, IARC Scientific Publication
  • [2] Batista CKLP, 2006, BRAZ J MED BIOL RES, V39, P1475
  • [3] Bernatsky S, 2008, J RHEUMATOL, V35, P11
  • [4] COGGINS PR, 1959, CANCER CHEMOTH REP, P9
  • [5] Churg-Strauss syndrome with poor-prognosis factors:: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients
    Cohen, Pascal
    Pagnoux, Christian
    Mahr, Alfred
    Arene, Jean-Pierre
    Mouthon, Luc
    Le Guern, Veronique
    Andre, Marie-Helene
    Gayraud, Martine
    Jayne, David
    Blockmans, Daniel
    Cordier, Jean-Franois
    Guillevin, Loic
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (04): : 686 - 693
  • [6] COHEN SM, 1992, CANCER RES, V52, P3577
  • [7] CYCLOPHOSPHAMIDE CYSTITIS - IDENTIFICATION OF ACROLEIN AS THE CAUSATIVE AGENT
    COX, PJ
    [J]. BIOCHEMICAL PHARMACOLOGY, 1979, 28 (13) : 2045 - 2049
  • [8] The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review
    de Groot, K
    Adu, D
    Savage, COS
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (10) : 2018 - 2027
  • [9] De Menthon M, 2009, APMIS, V117, P72
  • [10] Cyclophosphamide and cancer: golden anniversary
    Emadi, Ashkan
    Jones, Richard J.
    Brodsky, Robert A.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (11) : 638 - 647